Effect of oral CDP-choline on visual function in young amblyopic patients
- 299 Downloads
The purpose of the study was to evaluate the effect on visual function of orally administered CDP-choline in addition to patching for the treatment of amblyopia in children.
This was an open label parallel group study comparing patching plus oral CDP-choline with patching alone. Sixty-one participants (aged between 5 and 10 years) suffering from anisometropic or strabismic amblyopia were divided at random into two groups: Group A, 800 or 1,200 mg (according to the body weight) of orally administered CDP-choline and 2-h patching a day; Group B, 2-h patching a day. Both groups were treated for 30 consecutive days. A follow-up visit was set 60 days after the treatment was discontinued. The main outcome measure was the change in visual acuity of amblyopic eyes as measured by Snellen’s E charts. The secondary outcome measures were changes in the visual acuity of amblyopic eye as measured by isolated letters (Snellen’s E) and changes in the contrast sensitivity of amblyopic eyes.
The addition of CDP-choline to patching therapy was not found to be more effective than patching alone after 30-day treatment. The present results showed that adding CDP-choline to patching stabilised the effects obtained during the treatment period. In fact, whereas the participants treated only with patching showed a decrease in visual acuity at 90 days, these receiving CDP-choline and patching combined appeared to maintain the results obtained (two-way ANOVA: P = 0.0042). Similar results were obtained when measuring visual acuity by isolated Snellen’s E letters.
In amblyopic patients, CDP-choline combined with patching contributes to obtaining more stable effects than patching alone.
KeywordsCDP-choline Citicoline Amblyopia Medical treatment Visual acuity
The study was in part financially supported by Tubilux Pharma S.p.A.
- 1.Snowdon SK, Stewart-Brown SL (1997) Preschool vision screening. Health Technol Assess 1:1–85Google Scholar
- 3.Adams DL (2005) Normal and abnormal visual development. In: Taylor D, Hoyt CS (eds) Pediatric ophthalmology and strabismus. Elsevier Saunders, Edinburgh, pp 9–22Google Scholar
- 4.Repka MX (2005) Amblyopia management. In: Taylor D, Hoyt CS (eds) Pediatric ophthalmology and strabismus. Elsevier Saunders, Edinburgh, pp 862–868Google Scholar
- 5.Secades JJ (2001) CDP-choline update and review of its pharmacology and clinical use. Methods Find Exp Clin Pharmacol 23 [Suppl B]:1–53Google Scholar
- 12.Covelli GP, De Gregorio F, Grechi G, Pecori Giraldi J (1989) Efficacia della citicolina nei difetti perimetrici a settore. Boll Ocul 68 [Suppl 4]:353–361Google Scholar
- 13.Virno M, Pecori Giraldi J, Liguori A, De Gregorio F (2000) The protective effect of citicoline on the progression of the perimetric defects in glaucomatous patients (perimetric study with a 10-year follow-up). Acta Ophthalmol Scand 78 [Suppl]:56–57Google Scholar
- 14.Brogliatti B, Rolle T, Cantatore A, Bianco M (1991) Citicolina versus gangliosidi versus GM1: effetti sulla sensibilità retinica centrale in pazienti glaucomatosi. Boll Ocul 70 [Suppl 2]:1–8Google Scholar
- 30.Nguyen-Legros J, Harnois C, DiPaolo T, Simon A (1993) The retinal dopamine system in Parkinson’s disease. Clin Vis Sci 8:1–12Google Scholar